Cibinetide

Cibinetide (ARA290) is an erythropoietin (EPO) derivative that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. ICibinetide can be used in the research of neurological disorders^[1][2][3]. In Vitro:Cibinetide (ARA290) enhances the proliferation, migration, and resistance to H₂O₂-induced apoptosis of endothelial colony-forming cells (ECFCs)^[1]. Cibinetide (ARA290) is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects^[2]. In Vivo:After ECFC transplantation to mice with CLI, a single Cibinetide (ARA290) injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation^[1]. Cibinetide (ARA290; 30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. Cibinetide significantly decreases glucose AUCs in IPGTT in GK rats^[2]. Low-dosage Cibinetide (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. Cibinetide-treating group (70 μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way^[3].